2-(3-Chloropropyl)-2,5,5-trimethyl-1,3-dioxane

We are 2-(3-Chloropropyl)-2,5,5-trimethyl-1,3-dioxane CAS:88128-57-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Product Name: 2-(3-Chloropropyl)-2,5,5-trimethyl-1,3-dioxane
Synonym: Chloroket; Intermediates of Mifepristone
Cas No.: 88128-57-8
Formula: C₁₀H₁₉ClO₂
MW: 206.71
EINECS No.:417-650-1

HS Code: 2932999099

UN No.: N.A
Hazard class: Non-dangerous goods
 
Specification

 
Application
Intermediates of Mifepristone.
 
Packaging
25 kg/barrel, can also be packaged according to customer requirements. 
 
Storage
Store in a cool, ventilated warehouse. 
Keep away from fire and heat. 
The temperature should not exceed 37 °C. 

Related News: According to statistics, in the ten years from 2008 to 2017, a total of 13 “China Class 1” small-molecule chemical drugs were independently researched and developed by domestic enterprises in China and approved by the CFDA; in 2018, there were 10 varieties of domestic Class 1 new drugs. Approved for listing in China.2,4-Dichloro-5-nitrobenzotrifluoride CAS:400-70-4 Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.3-fluorobenzoato de metilo CAS:455-68-5 Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.5-Fluoro-2-oxindole CAS:56341-41-4 “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.